Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis.
NAPSI
PASI
PSSI
difficult locations
ppPASI
psoriasis
real-life
sPGA-G
tildrakizumab
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
07 May 2022
07 May 2022
Historique:
received:
21
04
2022
revised:
04
05
2022
accepted:
05
05
2022
entrez:
14
5
2022
pubmed:
15
5
2022
medline:
15
5
2022
Statut:
epublish
Résumé
Tildrakizumab, an IL-23 inhibitor, is effective and safe for the improvement of moderate-to-severe chronic plaque psoriasis. However, little evidence is available on the use of this biologic in psoriasis in difficult-to-treat locations. In this retrospective analysis, we treated patients with 100 mg tildrakizumab at Day 0, after 4 weeks and every 12 weeks thereafter. Disease severity and treatment response was assessed by the Psoriasis Area and Severity Index (PASI), the static Physician's Global Assessment of Genitalia (sPGA-G), the Psoriasis Scalp Severity Index (PSSI), Nail Psoriasis Severity Index (NAPSI) and the Palmoplantar Psoriasis Area and Severity Index (ppPASI) at baseline and after 4, 12 and 28 weeks. We followed 18 patients (mean age 49.1 ± 12.7 years, 61.1% male) with psoriasis localized to the genital region (N = 7), scalp (N = 6), nails (N = 5) and palmar/plantar areas (N = 7). PASI score decreased from 11.5 at baseline to 3.1 and 2.4 at 12 and 28 weeks. Tildrakizumab treatment decreased sPGA-G (3.3 to 0.2), PSSI (36.2 to 2.7), NAPSI (48.4 to 15.7) and ppPASI (5.3 to 0) from baseline to 28 weeks, respectively. Data from this real-life retrospective analysis shows that tildrakizumab is an effective option for the management of psoriasis in difficult-to-treat areas.
Identifiants
pubmed: 35566756
pii: jcm11092631
doi: 10.3390/jcm11092631
pmc: PMC9100809
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Almirall (Italy)
ID : N/A
Références
Dermatol Ther (Heidelb). 2021 Jun;11(3):833-844
pubmed: 33914293
J Eur Acad Dermatol Venereol. 2015 Sep;29(9):1763-70
pubmed: 25693783
J Dermatolog Treat. 2018 Dec;29(8):754-760
pubmed: 29565190
J Am Acad Dermatol. 2012 Jul;67(1):86-92
pubmed: 22014541
Dermatology. 2022;238(4):615-619
pubmed: 34775387
Arthritis Rheum. 2006 Apr;54(4):1328-33
pubmed: 16575858
Patient Prefer Adherence. 2013;7:199-205
pubmed: 23508007
Dermatol Ther. 2022 Jun;35(6):e15488
pubmed: 35384168
Dermatol Ther (Heidelb). 2016 Dec;6(4):627-638
pubmed: 27573260
J Am Acad Dermatol. 2018 Jan;78(1):90-99.e1
pubmed: 28993005
J Am Acad Dermatol. 2007 Jul;57(1):1-27
pubmed: 17572277
Br J Dermatol. 2021 Aug;185(2):323-334
pubmed: 33544883
J Dtsch Dermatol Ges. 2011 Jan;9(1):70-4
pubmed: 20374417
J Drugs Dermatol. 2017 Aug 1;16(8):793-799
pubmed: 28809994
J Am Acad Dermatol. 2021 Jul;85(1):135-143
pubmed: 33482253
Nature. 2015 May 14;521(7551):222-6
pubmed: 25754330
Am J Clin Dermatol. 2001;2(3):159-65
pubmed: 11705093
Br J Dermatol. 2019 Aug;181(2):358-365
pubmed: 30430557
JAMA Dermatol. 2018 Jun 1;154(6):676-683
pubmed: 29799960
N Engl J Med. 2017 Apr 20;376(16):1551-1560
pubmed: 28423301
Br J Dermatol. 2018 Oct;179(4):844-852
pubmed: 29747232
Dermatol Ther. 2021 Jan;34(1):e14584
pubmed: 33236471
Clin Exp Dermatol. 2016 Jul;41(5):486-9
pubmed: 26890045
J Eur Acad Dermatol Venereol. 2017 May;31(5):774-790
pubmed: 28244153
Lancet. 2015 Sep 5;386(9997):983-94
pubmed: 26025581
J Dermatolog Treat. 2022 Feb;33(1):531-534
pubmed: 32419527
J Invest Dermatol. 2013 Feb;133(2):377-85
pubmed: 23014338
BMC Dermatol. 2020 May 20;20(1):3
pubmed: 32434510
Br J Dermatol. 2019 Mar;180(3):647-656
pubmed: 30188572
J Am Acad Dermatol. 2009 Jun;60(6):962-71
pubmed: 19375191
Br J Dermatol. 2001 Oct;145(4):546-53
pubmed: 11703279
J Drugs Dermatol. 2022 Feb 1;21(2):146-150
pubmed: 35133106
J Dermatolog Treat. 2020 Dec;31(8):763-768
pubmed: 31268369
Dermatol Ther. 2020 Mar;33(2):e13216
pubmed: 31899569
Psoriasis (Auckl). 2018 Aug 28;8:41-47
pubmed: 30214891
Drugs Context. 2021 May 21;10:
pubmed: 34104197
Expert Opin Biol Ther. 2022 Apr;22(4):547-554
pubmed: 35043741
Clin Dermatol. 2017 Jan - Feb;35(1):19-27
pubmed: 27938808
Int J Dermatol. 2021 Oct 11;:
pubmed: 34632570
Int J Mol Sci. 2017 Nov 16;18(11):
pubmed: 29144382
J Eur Acad Dermatol Venereol. 2015 Feb;29(2):353-360
pubmed: 24846518
Am J Clin Dermatol. 2016 Aug;17(4):349-58
pubmed: 27113059
Br J Dermatol. 2015 Oct;173(4):930-9
pubmed: 26042589
J Eur Acad Dermatol Venereol. 2020 Dec;34(12):e803-e805
pubmed: 32432798
Lancet. 2017 Jul 15;390(10091):276-288
pubmed: 28596043
Australas J Dermatol. 2021 Aug;62(3):390-393
pubmed: 34114645
Br J Dermatol. 2021 Mar;184(3):425-436
pubmed: 32479641
Semin Arthritis Rheum. 2014 Oct;44(2):162-9
pubmed: 24932889
Dermatol Ther. 2019 May;32(3):e12914
pubmed: 30968520
Ann Rheum Dis. 2012 Apr;71(4):553-6
pubmed: 22156725
Dermatol Ther (Heidelb). 2020 Aug;10(4):663-670
pubmed: 32415575
J Am Acad Dermatol. 2003 Aug;49(2):206-12
pubmed: 12894066
Expert Opin Biol Ther. 2022 Mar;22(3):367-376
pubmed: 34607513
J Eur Acad Dermatol Venereol. 2009 Sep;23 Suppl 1:9-13
pubmed: 19686380